Navigation Links
Boston Scientific Announces Results For Second Quarter Ended June 30, 2013
Date:7/25/2013

place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; markets for our products; expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our restructuring program; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.
We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements contained in this press release.

Use of Non-GAAP Financial InformationA reconciliation of the company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the company's use of these non
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. American Laboratory Trading Continues Steady Growth with Expansion in Boston
2. Affordable Scrum Training in Boston,MA by Conscires Agile Practices
3. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston
4. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA
5. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials
6. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center
7. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
8. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
9. Boston College researchers unique nanostructure produces novel plasmonic halos
10. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th
11. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... October 24, 2014 ... ) has announced the addition of the  ... And Other 2-D Nanomaterials "  report to ... , ,CNTs and graphene are the strongest, ... man, with a performance-per-weight greater than any ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... Gene scanning techniques developed by Professor Ian Day and ... have a major impact on healthcare in the future. ... by Professor Day and his team in the Human ... been successfully applied to search for rare genetic mutations ...
... volume says Dutch researcher Bas Tomassen. He investigated the uptake ... and human cells. , Cell volume is the outcome ... the cell plasma membrane. A cell can regulate its volume ... Exactly how this process works is still not known. Bas ...
... Scientists at the Albert Einstein College of Medicine have ... causes tuberculosis may soon be able to resist the ... why several disease-causing microbes, including Shigella and E. coli, ... research effort was led by Dr. John S. Blanchard, ...
Cached Biology News:New gene scanning technology marks a major advance in disease research 2Water management in cells 2Einstein researchers identify new way that bacteria develop resistance to antibiotics 2
... 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat ... phenol treatment followed by ethanol precipitation. Storage ... 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, 50% ... ice. Store at -20C. Unit Definition: One ...
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: